The Role of CBFb-MYH11 in Acute Myeloid Leukemia
CBFb-MYH11 在急性髓系白血病中的作用
基本信息
- 批准号:7019382
- 负责人:
- 金额:$ 26.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-04-15 至 2011-02-28
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Translocations affecting a core binding factor (CBF) gene are one of the most frequent genetic aberrations in human acute myeloid leukemia (AML), accounting for up to 25% of all AMLs. Nearly half of these are associated with translocations affecting chromosome 16, resulting in expression of the fusion protein CBF(- MYH11. The overall objective of the proposed studies is to define the signaling pathways and downstream target genes that are affected by CBF(-MYH11, to evaluate the role of these regulated genes in leukemic stem cell self-renewal, survival and differentiation, and to identify the signaling pathways that cooperate with CBFP-MYH11 in leukemogenesis. To accomplish this goal, we propose to use the model of fusion gene expression in human CD34+ cells we have developed, to study the pre-leukemia that is a result of CBF(- MYH11 expression prior to the acquisition of cooperating mutations that lead to frank leukemia. We have successfully used this system to model the related leukemia fusion protein AML1-ETO. The specific aims of this proposal are as follows: Aim 1: Define the signaling pathways downstream of CBF(-MYH 11. Expression of CBF(-MYH11 in human CD34+ cells leads to their continued growth in vitro for an extended period of greater than five months. These cells will be characterized in terms of their proliferation, survival and differentiation, and compared to the long-term cultures initiated by the related CBF fusion, AML1-ETO. Aim 2: Identify target genes of CBFp-MYHl1 and analyze their role in CBF(-MYH11 -induced proliferation. A common gene expression profile will be identified by comparing the transcriptome of CD34+ cells from our long-term cultures with normal CD34+ cells. We will analyze the contribution of these regulated target genes by over-expressing those that are repressed, and conversely by knocking-down those genes that become upregulated. Aim 3: Identify the signaling pathways that cooperate with CBF(-MYHl1 in leukemogenesis. The pre-leukemic cultures expressing CBF(-MYH11 will serve as the background in which cooperating mutations will be tested. To identify specific signals that will cooperate in the transformation to acute leukemia, defined genetic elements and saturating retroviral mutagenesis will be used.
描述(由申请方提供):影响核心结合因子(CBF)基因的易位是人类急性髓性白血病(AML)中最常见的遗传畸变之一,占所有AML的25%。其中近一半与影响16号染色体的易位有关,导致融合蛋白CBF(-MYH 11)的表达。这些研究的总体目标是确定受CBF(-MYH 11)影响的信号通路和下游靶基因,评估这些受调控基因在白血病干细胞自我更新、存活和分化中的作用,并鉴定与CBFP-MYH 11在白血病发生中协同作用的信号通路。为了实现这一目标,我们建议使用我们已经开发的人CD 34+细胞中的融合基因表达模型来研究白血病前期,该白血病前期是在获得导致明显白血病的协同突变之前CBF(-MYH 11)表达的结果。我们已经成功地利用该系统来模拟相关的白血病融合蛋白AML 1-ETO。该提案的具体目标如下:目标1:定义CBF(-MYH 11)下游的信号通路。CBF β-MYH 11在人CD 34+细胞中的表达导致其在体外持续生长超过5个月。这些细胞将在其增殖、存活和分化方面进行表征,并与由相关CBF融合AML 1-ETO启动的长期培养物进行比较。目的2:鉴定CBFp-MYH 11的靶基因,并分析其在CBFp-MYH 11诱导的细胞增殖中的作用。将通过比较来自我们的长期培养物的CD 34+细胞与正常CD 34+细胞的转录组来鉴定共同的基因表达谱。我们将通过过度表达那些被抑制的基因来分析这些受调节的靶基因的贡献,相反,通过敲低那些上调的基因来分析这些靶基因的贡献。目的3:研究CBF(-MYH 11)在白血病发病中的作用。表达CBF(-MYH 11)的白血病前培养物将作为检测协同突变的背景。为了鉴定将在向急性白血病的转化中合作的特定信号,将使用确定的遗传元件和饱和逆转录病毒诱变。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES C MULLOY其他文献
JAMES C MULLOY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES C MULLOY', 18)}}的其他基金
Instructive role of MLL fusion proteins in lineage determination and leukemogenesis
MLL 融合蛋白在谱系确定和白血病发生中的指导作用
- 批准号:
9290731 - 财政年份:2017
- 资助金额:
$ 26.6万 - 项目类别:
Instructive role of MLL fusion proteins in lineage determination and leukemogenesis
MLL 融合蛋白在谱系确定和白血病发生中的指导作用
- 批准号:
10115634 - 财政年份:2017
- 资助金额:
$ 26.6万 - 项目类别:
Leukemia stem cell polarity and differentiation therapy
白血病干细胞极性与分化治疗
- 批准号:
10227111 - 财政年份:2017
- 资助金额:
$ 26.6万 - 项目类别:
Genotype and phenotype of chemoresistant AML
化疗耐药性 AML 的基因型和表型
- 批准号:
8618872 - 财政年份:2013
- 资助金额:
$ 26.6万 - 项目类别:
Genotype and phenotype of chemoresistant AML
化疗耐药性 AML 的基因型和表型
- 批准号:
8528938 - 财政年份:2013
- 资助金额:
$ 26.6万 - 项目类别:
The Role of MLL-AF9 in Acute Myeloid Leukemia
MLL-AF9 在急性髓系白血病中的作用
- 批准号:
7698026 - 财政年份:2009
- 资助金额:
$ 26.6万 - 项目类别:
相似国自然基金
RKTG对ERK信号通路的调控和肿瘤生成的影响
- 批准号:30830037
- 批准年份:2008
- 资助金额:190.0 万元
- 项目类别:重点项目
相似海外基金
Cancer Prevention Agent Development Program: Early Phase Clinical Research
癌症预防剂开发计划:早期临床研究
- 批准号:
8566568 - 财政年份:2012
- 资助金额:
$ 26.6万 - 项目类别:
Cancer Prevention Agent Development Program: Early Phase Clinical Research
癌症预防剂开发计划:早期临床研究
- 批准号:
8566553 - 财政年份:2012
- 资助金额:
$ 26.6万 - 项目类别:
Cancer Prevention Agent Development Program: Early Phase Clinical Research
癌症预防剂开发计划:早期临床研究
- 批准号:
8566562 - 财政年份:2012
- 资助金额:
$ 26.6万 - 项目类别:
Cancer Prevention Agent Development Program: Early Phase Clinical Research
癌症预防剂开发计划:早期临床研究
- 批准号:
8566564 - 财政年份:2012
- 资助金额:
$ 26.6万 - 项目类别:
Cancer Prevention Agent Development Program: Early Phase Clinical Research
癌症预防剂开发计划:早期临床研究
- 批准号:
8566560 - 财政年份:2012
- 资助金额:
$ 26.6万 - 项目类别:
Basic and clinical research for prevention of carcinogenesis aiming at extinction of head and neck squamous cell carcinoma.
以消灭头颈部鳞状细胞癌为目标的预防癌变的基础和临床研究。
- 批准号:
15591792 - 财政年份:2003
- 资助金额:
$ 26.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)